Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
>
Nightmare bacteria
Nightmare bacteria
Read also
NRx Pharmaceuticals
NRx Pharmaceuticals Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product
Akari Therapeutics
Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
Breakthrough Therapy Designation To Povetacicept
Vertex: FDA Grants Breakthrough Therapy Designation To Povetacicept
IGC Pharma
IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology
